Renal Cancer
Comparing Immuno-oncology Combination Therapy With Tyrosine Kinase Inhibitor Monotherapy for Advanced Renal Cell Carcinoma.
January 2, 2025
Immunohistochemical Analysis of a1-Acid Glycoprotein and Tumor Associated Macrophages in Clear Cell Renal Cell Carcinoma.
December 31, 2024
Rhabdoid Tumor of the Kidney and Soft Tissues: Results from National Wilms Tumor Study-5 and Children's Oncology Group Study AREN0321.
December 31, 2024
Real-World Oncological Outcomes of Nivolumab Plus Ipilimumab in Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study in Japan.
December 30, 2024
Development and validation of a prognostic model based on m6A-related lncRNAs to predict prognosis for papillary renal cell cancer patients.
December 30, 2024
Using three-dimensional virtual imaging of renal masses to improve prediction of robotic-assisted partial nephrectomy Tetrafecta with SPARE score.
December 27, 2024
Clinicopathologic Study of 28 Cases of Tubulocystic Renal Cell Carcinoma: Is It Time to Reclassify It as a Tubulocystic Renal Cell Tumor?
December 27, 2024
Imaging and Nonsurgical Management of Renal Masses.
December 26, 2024
Metastatic risk in clear cell renal cell carcinoma: a tool incorporating sex, size, and grade.
December 26, 2024
Cytoreductive Nephrectomy Following Immunotherapy: Evolution, Pearls, and Pitfalls of Treatment.
December 25, 2024
Racial differences in real-world outcomes of first-line therapies for advanced renal cell carcinoma.
December 24, 2024
A novel preoperative evaluation technique for partial nephrectomy: three-dimensional extended renal tumor plane.
December 24, 2024
Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States.
December 23, 2024
Avelumab + axitinib vs sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase 3 JAVELIN Renal 101 trial.
December 23, 2024
Integrating artificial intelligence in renal cell carcinoma: evaluating ChatGPT's performance in educating patients and trainees.
December 20, 2024